Antifungal activities of Equol against <i>Candida albicans in vitro</i> and <i>in vivo</i>-Reference-Cited by-同舟云学术

Antifungal activities of Equol against Candida albicans in vitro and in vivo

Published:2024-09-12 Issue: Volume: Page:
ISSN:2150-5594
Container-title:Virulence
language:en
Short-container-title:Virulence

Author:

Wang Fen¹,Zhang Jinping²,Zhang Qian³,Song Zhangyong²⁴⁵,Xin Caiyan²^ORCID

Affiliation:

1. Nanobiosensing and Microfluidic Point-of-Care Testing Key Laboratory of LuZhou, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Sichuan Province, China

2. School of Basic Medical Science, Southwest Medical University, Luzhou, People’s Republic of China

3. Department of blood transfusion, Zhijiang people’s hospital, Yichang, China

4. Technical Platform for the Molecular Biology, Research Core Facility, Southwest Medical University, Luzhou, People’s Republic of China

5. Hemodynamics and Medical Engineering Combination Key Laboratory of Luzhou, Luzhou, People’s Republic of China

Funder

Sichuan Science and Technology Program

Luzhou

Technology Strategic Cooperation Project of Luzhou Municipal People’s Government Southwest Medical University

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/21505594.2024.2404256

Reference47 articles.

1. World Health Organization (WHO). WHO fungal priority pathogens list to guide research development and public health action. 2022. Available online: https://www.who.int/publications/i/item/9789240060241 (accessed on 16 November 2022).

2. Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond

3. Pathogenesis and virulence of Candida albicans

4. Invasive candidiasis in critical care: challenges and future directions;Logan C;Intensive Care Med,2020

5. Candida albicans biofilms and polymicrobial interactions